Allogene Therapeutics, Inc. announced an encore presentation of data from the Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A at the European Hematology Association (EHA) Hybrid Congress on June 8--11, 2023 in Frankfurt, Germany. The ALPHA/ALPHA 2 trials were designed to assess the safety, tolerability, and preliminary efficacy at increasing dose levels of ALLO-501 and ALLO-501A, allogeneic CAR T cell product candidates that target CD19. In addition to exploring cell doses, these studies evaluated escalating doses of ALLO-647, Allogene's proprietary investigational lymphodepleting antibody designed to prevent premature rejection of AlloCAR T cells, in combination with fludarabine and cyclophosphamide.

ALLO-501A, a next-generation anti-CD19 AlloCAR T(TM), eliminates the rituximab recognition domains in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure. This product candidate is currently being studied in an ongoing Phase 2 trial. In June 2022, the U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to ALLO-501A in r/r LBCL.